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ACELLULAR AND “LOW” PERTUSSIS VACCINES: ADVERSE EVENTS AND THE ROLE OF MUTATIONS
Hisako G. HIGASHI(1), Expedito LUNA(2), Alexander R. PRECIOSO(3), Marluce VILELA(4), Flávia S. KUBRUSLY(5), Waldely O. DIAS(5) & Isaias RAW(5)
SUMMARY
Objective: to discuss the current PAHO recommendation that does not support the substitution of traditional cellular DTP vaccine 
by acellular DTP, and the role of mutations, in humans, as the main cause of rare adverse events, such as epileptic-like convulsions, 
triggered by pertussis vaccine.
Data review: the main components related to toxic effects of cellular pertussis vaccines are the lipopolysaccharide of bacterial 
cell wall and pertussis toxin. The removal of part of lipopolysaccharide layer has allowed the creation of a safer cellular pertussis 
vaccine, with costs comparable to the traditional cellular vaccine, and which may be a substitute for the acellular vaccine.
Conclusion: The new methodology introduced by Instituto Butantan allows for the development of a new safer pertussis vaccine 
with low LPS content (Plow), and the use of the lipopolysaccharide obtained in the process in the production of monophosphoryl lipid 
A. This component has shown potent adjuvant effect when administered together with influenza inactivated vaccine, making possible 
to reduce the antigen dose, enhancing the production capacity and lowering costs.
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DTP TOxINS ACTION MECHANISMS
Clostridium tetani is a rod-shaped, anaerobic bacterium that produces 
a potent biological toxin, and is the causative agent of tetanus. The 
tetanus toxin is internalized in the postsynaptic neuromuscular neuron 
binding to a protein, synaptobrevin, located on the surface of synaptic 
vesicles, where acetylcholine is stored. Tetanus toxin is a proteolytic 
enzyme, activated by zinc ions. Its activity is extremely specific, it cleaves 
synaptobrevin, impeding its liberation and causing muscle paralysis.
Corynebacterium diphtheriae produces diphtheria toxin, which 
acts as an enzyme that transfers adenosyl-diphosphate-ribase (ADPR) 
of NAD (nicotinamide-adenine-dinucleotide) to the elongation factor 2 
and prevents this factor from adding amino acids to the protein chain, 
thus inhibiting protein synthesis in target cells.
Bordetella pertussis produces pertussis toxin, which like diphtheria 
toxin, is an enzyme that transfers ADPR to protein targets. Unlike 
diphtheria toxin, pertussis toxin targets a large number of G proteins, 
which are part of the receptors present on the membrane of several cell 
types. When the mediators bind to the receptor, the separate chains of G 
proteins, α chain, activates adenylate cyclase, that catalyses the formation 
of cyclic adenylic acid (cAMP). The two other chains of G proteins (β 
and γ) activate another enzyme, phospholipase C producing inositol 
triphosphate that liberates Ca2+ in the endoplasmic reticulum activating 
the phosphorylation of other proteins, among them, cytoskeleton cells. 
The blockade of receptors elicited by pertussis impedes the separation 
of G protein chains, inhibiting the production of adenylate cyclase and 
the signs mediated by the increase of Ca2+ and K+ inside the cells. The 
production of cAMP acts in the transmission of the signal to the cell’s 
interior: Gi (present in the α2 adrenergic receptors, cholinergicmusca-
rinic, dopaminergic-D2, glutaminergic,5H-T serotonin, opiate receptors 
linked to pain, cannabinoid, melatonin, somatostatin, TSH liberation 
factor), the Gt, or retina transducine and more than a hundred of G 
receptors that detect taste and smell, affecting therefore a large number 
of organs. cAMP activates the phosphorylation of several proteins that 
regulate glucose and fatty acids metabolism and the contraction of smooth 
muscle. Unlike tetanus and diphtheria toxins, that present a specific 
point of action, pertussis toxin blocks several neurotransmitters, affects 
hormone functions and reduces phagocytic activity5,11.
DTP VACCINE
Diphtheria-tetanus-pertussis (DTP) vaccine was the first combination 
vaccine, introduced more than 65 years ago, and protects against 
diseases caused by the three bacteria5. It has been recognized since the 
development of the vaccine against whooping cough that, unlike the 
protective effect of tetanus and diphtheria toxoids, immunization with 
pertussis anatoxin alone was not sufficient for protective immunity. 
Cellular DTP vaccine contains intact heat or formaldehyde inactivated 
Bordetella pertussis and tetanus and diphtheria toxoids. This combined 
vaccine has been universally used in the first year of life to prevent 
morbidity and mortality by whooping cough, tetanus and diphtheria 
diseases. Instituto Butantan has established new production plants for 
each one of the DTP vaccine antigen components. New plants have 
also been established for other antigens, that in the near future will be 
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assembled in a 5-valent vaccine (DTP, hepatitis B and Hib), to supply the 
Brazilian demand. Optimization of production processes, which has been 
attained after years of experience, has allowed for a 3-4 fold increase in 
production capacity, well above national demand. 
Instituto Butantan’s DTP vaccine has been administered free of 
charge to almost 100% of newborn children in Brazil in the past 15 
years. More than 50 million doses have been used, without major adverse 
effects. According to the Brazilian Ministry of Health pertussis incidence 
has declined from 10.8 in 1990 to 0.55 per 100,000 in 2005. In the same 
period, diphtheria incidence decreased from 0.45 to 0.01 per 100,000, 
and tetanus incidence from 1.0 to 0.25 per 100,000.
DTP vaccine changes from manufacturer to manufacturer, because 
of the different Bordetella pertussis strains used for production. Some 
manufacturers even use two different strains. There is a rare, although 
serious risk of a severe adverse event related to the pertussis component 
of DTP. The risk of encephalopathy and convulsions varies according to 
the origin of the vaccine and the strain used for production. These risks 
have been estimated to be 1/19,496 for fever convulsions, 1/76,133 for 
convulsion without fever and 3/106 for encephalopathy5.
ACELLULAR PERTUSSIS VACCINE (aP)
Fear of whole cell pertussis vaccine (wP) toxicity lead, in the 
seventies, to a decline in vaccine coverage in some countries, increasing 
whooping cough incidence. To overcome the severe toxicity problem, 
SATO et al.12 developed, in Japan, an acellular vaccine, containing 
only two major virulence factors of the bacteria, the pertussis toxin 
(PT) and the filamentous hemagglutinin (FHA), related to the bacterial 
colonization. The adhesins allow the bacteria to bind the cilliated 
epithelium of trachea as well as leukocytes. Pertussis toxin is an AB 
type toxin, where the B subunit binds to receptors located in the target 
cells in order to be endocytosed. The A subunit is the toxin itself, 
with an ADP-ribosyl transferase, that leads to an increase in cAMP, 
an important intracellular mediator, that in bronchial mucosal cells is 
responsible for the production of mucus. This toxin also deregulates 
macrophages, resulting in resistance to phagocytosis. FHA binds 
to macrophage membranes and inhibits Th1 responses. Bordetella 
pertussis presents some other virulence factors: fimbriae (Fim), 
agglutinogens and pertactin (69Kd outer membrane protein), present 
on the bacterial surface, that allow binding and invasion of host cells; 
adenylate cyclase, which catalyses the production of cAMP from ATP 
and induces leukocytosis and insulin secretion, enhancing the immune 
response; tracheal cytotoxin, that paralyzes tracheal epithelium ciliae; 
and dermo-necrotic toxin or thermolabil toxin, that induces dermal 
necrosis and vasoconstriction. The Bordetella resistance to serum 
killing, antigen (BrkA) protects bacteria from complement attack. 
SATO’s12 studies have demonstrated that pertussis anatoxin and FHA 
are enough to induce protective immunity. Currently, besides these two 
antigens, some acellular vaccines include pertactin and fimbriae. All 
acellular vaccines are inactivated by formaldehyde or glutaraldehyde 
and H2O2.
COST-BENEFIT DTP VS DTPa
The aP, with almost similar efficacy of the wP and lower reactogenicity, 
has been widely used by industrialized countries in combination with 
tetanus and diphtheria toxoids (DTaP vaccine). However, the profit from 
production of aP vaccine is extremely low, around ten times less than 
the traditional wP and its substitution in accordance with the price of 
Fundo Rotatório da Organização Panamericana de Saúde (OPAS), would 
increase the cost from US$ 0.15 to US$ 8.15.
For Brazil, which administers five pertussis doses for each child, this 
would represent a cost of 163 million dollars / year and the importation of 
DTaP would in turn cause an increase of more than 50 times in the expense. 
In October of 2007, the Technical Committee Adviser in Immunizations 
of the OPAS and members of the World Health Organization (WHO) 
both composed of specialists from several countries joined in Washington 
and concluded: “There is no reason for countries to substitute the whole 
cell pertussis vaccine for acellular pertussis vaccine. The use of the wP 
presents a much higher relation of cost-effectiveness10.”
DTP CLINICAL TRIALS
A mistake in the child vaccine production may put at risk all the 
infant population born at that year. No less serious is the importation 
of vaccine in bulk without activity, as happened to Butantan Institute 
before production of its own vaccine preparation had been optimized. 
Fortunately, the inactive lot was detected in time avoiding the 
administration of a vaccine that, although harmless, did not give the 
expected protection.
WHO recommends that each country has a procedure to ensure quality 
control before releasing each lot of vaccine. Unfortunately, application of 
such procedures remains limited. Non-producer countries, normally the 
poorest, are subject to trust in the supplier. Brazil established in 1984 the 
National Institute of Quality Control in Health (INCQS), which operates 
along with Oswaldo Cruz Foundation. The INCQS showed that several 
national and imported vaccines, and specially the hyperimmune serums 
against serpent poisons, were inactive and frequently contaminated, 
which led to the closure of many small producers. Recently, similar 
events occurred in India with DTP manufactures.
Before being released by the producer, the wP basically passes 
through three laboratory tests: (i) weight gain in mice, a non-specific 
toxicity test that evaluates loss of weight in mice immunized with the 
vaccine test lot; (ii) pyrogen testing in rabbits, with the induction of 
fever to evaluate the level of endotoxin in the product; and (iii) the 
mouse protection test, using an intracerebral challenge with a virulent 
B. pertussis strain. These tests are repeated by the INCQS for samples 
of each lot of vaccine supplied by Instituto Butantan, before its release. 
Vaccine toxicity is most often due to the presence of lipopolysaccharide 
(LPS), present in the cell walls of all Gram-negative bacteria. LPS binds 
to Toll-like receptor 4 found on the surface of leucocytes, activating 
simultaneously two branches of intracellular signaling: one mediated 
by the signaling adaptor MyD88, which induces the production of 
inflammatory cytokines, and other mediators of the inflammatory 
cascade, and the second mediated by the adaptor TRIF, which induces 
interferon - β, and leads to activation of T cells, promoting the adaptive 
immune response 7.
Antibody responses are assumed to be related to protection against 
intracerebral challenge in mice immunized with the pertussis vaccine. 
It was demonstrated by Instituto Butantan,8 in mice immunized with a 
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BCG recombinant vaccine carrying the gene for production of the subunit 
S1 of the pertussis toxin, that this vaccine protects the mice against 
intracerebral challenge without producing antibodies and, therefore, 
reflects the action of components of the cellular immunity. This is now 
a candidate vaccine that, if administered during the first months of life 
as is true of BCG, would prevent whooping cough in the first months of 
life, before immunity is induced by the traditional vaccination scheme 
with DTP, which occurs after the second or third doses given at 4 and 6 
months, respectively.
DTP LOW - A NEW CELLULAR PERTUSSIS VACCINE
Undoubtedly LPS is one of the principal components responsible for 
the toxic effect of the cellular pertussis vaccine. During the isolation and 
purification of the protein antigens in the production of acellular vaccine, 
a major goal is the removal of the LPS. The Instituto Butantan recently 
developed a process that removes more than 95% of the LPS, without 
altering the ultramicroscopic structure of the bacterium, resulting in a 
cellular pertussis vaccine (Plow), which is much less toxic and equally 
effective in mice4 as measured by the intracerebral challenge. The new 
vaccine, combined with the tetanus and diphtheria toxoids (DTPlow), was 
demonstrated in a clinical trial to induce humoral and cellular immune 
responses similar to DTP and probably equal or superior than DTPa17. 
Importantly, the production of this vaccine did not alter the cost of the 
traditional DTP, allowing for its use in developing countries (Fig. 1).
In the new process, two other products are obtained, in the same 
line of production. From the culture supernatant of the bacterium, one 
obtains a preparation which contains the principal pertussis antigens - 
PT, FHA, pertactin and adenylate cyclase, constituting a new acellular 
pertussis vaccine (aP), equally of low cost. Studies in progress have 
demonstrated that is possible to produce for each 10 or 20 doses of the 
traditional wP or of the Plow, one dose of the aP vaccine. This vaccine 
may be used in children who present contraindications for vaccination 
with wP, or in adolescents3, and adults, in which the cellular component 
is not indicated.
The removed LPS of the bacterium can be processed into 
monophosphoryl-lipid A (MPLA), a powerful adjuvant, which has been 
evaluated in different vaccines and elicit the production of interferon 
- β and enhances T cell activation, without inducing an inflammatory 
response. In the Instituto Butantan, MPLA obtained from pertussis has 
been evaluated in mice, as an adjuvant component of an influenza vaccine. 
In this study, 0.01 μg of MPLA reduced by four times the necessary 
dose of vaccine16. A dose of classic wP contains around 400 μg of LPS, 
corresponding to 150-200 μg of MPLA. MPLA will be essential as an 
adjuvant to produce the Asian flu vaccine that have low immunogenic 
capacity, and which otherwise require, doses much higher than is true 
of the vaccine for seasonal influenza. Clinical trials of pertussis-derived 
MPLA are in progress. Reducing the dose of antigens in the seasonal 
influenza vaccine, and with the same financial resources, will allow 
inclusion of children of school age to participate in public vaccination 
campaigns against influenza. In addition to protecting children from 
influenza, including dissemination of the virus to family members, these 
campaigns help prevent secondary infections, such as pneumonia and 
middle ear infections that cause deafness.
MUTATIONS AND VACCINES ADVERSE EFFECTS
For many years, concerns have been raised about the risk of 
vaccine-induced childhood encephalopathy and epilepsy. Recently, 
“The Hannah Poling Case” in The United States had extensive media 
coverage9. When Hannah was at the age of 19 months she received five 
vaccines: diphtheria-tetanus-acellular pertussis; Haemophilus influenza 
type b (Hib); measles-mumps-rubella (MMR); varicella; and inactivated 
polio. Two days later, she was lethargic, irritable, and febrile. Ten days 
after vaccination, she developed a rash consistent with vaccine-induced 
varicella. Months later, with delays in neurologic and psychological 
development, she was diagnosed with encephalopathy caused by a 
mitochondrial enzyme defect. Her symptoms were compatible with 
autism spectrum. As Hannah´s parents believed that vaccines had 
triggered her encephalopathy they sued the Department of Health and 
Human Services (DHHS) for compensation under the Vaccine Injury 
Compensation Program (VICP) and won. Definitely, the encephalopathy 
was not caused by the vaccine, but its appearance after the vaccination 
can suggest that the vaccine accelerated the appearance of the symptoms 
of this genetic disease.
The association between vaccines and multiple sclerosis or autism 
has also generated much controversy1. In the case of autism, concern was 
raised that thimerosal-containing vaccines result in children developing 
neurodevelopmental disorders6. However, critical reviews show that 
neither immunization nor thiomersal exposure are linked to autism. It is 
worth saying that in developed countries such as Sweden and Denmark, 
Fig. 1 - Plow and monophosphoryl-lipid A production from pertussis.
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the diagnoses of autism began in the mid 1980s and continues to increase. 
However, thimerosal exposure in Sweden and Denmark (already low 
throughout the 1970s and 1980s) began to decrease in the late 1980s 
and has been eliminated since the early 1990s15. 
Another concern in vaccination is the observation of neurological 
disease, such as epilepsy, encephalitis, and encephalopathy, within a few 
days after DTP. Large-scale studies of this issue have produced conflicting 
results, although the recent consensus is that the risk of vaccine-induced 
encephalopathy and/or epilepsy, if it exists at all, is extremely low2,13,14. 
In fact, it was shown that encephalopathy in 11 out of 14 children 
studied, although previously attributed to vaccination, was in fact due 
to an inherited genetic defect of the α1chain of the gene SCN1, which 
is a voltage-gated sodium channel2. This mutation causes a clinical 
manifestation similar to the severe myotonic epilepsy of childhood.
These findings show that the serious side effects considered associated 
to the DTP vaccine must be in fact due to genetic mutations which are 
difficult to diagnose routinely. Therefore, the detection of these mutants at 
the moment should be performed by questioning about potential vaccine 
side effects occurrence among relatives. Anyway, the occurrence of side 
effects associated to vaccination always causes public distress, which 
can make the introduction of a new vaccine difficult, even if effective 
and safe, afterwards. The research on new vaccine formulations keeps 
as a goal the discovery of new formulations with no side effects, which 
is not always easily attainable.
RESUMO
Vacinas pertussis acelular e pertussis “low”: eventos adversos e o 
papel das mutações
Objetivo: Discutir as recomendações da WHO-OPAS que não 
consideram indicada a substituição da vacina DTP celular clássica pela 
DTP acelular e o papel de mutações, em humanos, como principal causa 
dos raros eventos de convulsões epileptiformes desencadeadas pela 
vacina pertussis.
Revisão dos dados: Os principais componentes relacionados aos 
efeitos tóxicos da vacina pertussis celular são o lipopolissacarídio da 
parede celular da bactéria e a toxina pertussis. A remoção de parte da 
camada lipopolissacarídica permitiu a criação de uma vacina pertussis 
celular, mais segura e de custo comparável ao da vacina celular 
tradicional, podendo substituir a vacina pertussis acelular.
Conclusão: A nova vacina pertussis, com baixo teor de LPS (Plow) 
desenvolvida pelo Instituto Butantan, além de oferecer uma vacina mais 
segura, permite o aproveitamento do lipopolissacarídeo para a produção 
de monofosforil lipídeo A. Esse componente mostrou-se potente como 
adjuvante e altamente eficiente quando administrado com a vacina de 
influenza, levando à possibilidade de se reduzir a dose de antígeno, 
aumentando a capacidade de produção e redução dos custos.
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